| DIRECT COMPETITOR COMPARISON | |
| AVII | LLY | GNTA.OB | ISIS | Industry | | Market Cap: | 163.44M | 42.97B | N/A | 1.10B | 165.99M | | Employees: | 83 | 40,500 | N/A | 300 | 95 | | Qtrly Rev Growth (yoy): | 22.80% | 6.80% | N/A | -9.10% | 20.50% | | Revenue (ttm): | 17.92M | 21.11B | N/A | 118.99M | 46.74M | | Gross Margin (ttm): | -25.49% | 82.33% | N/A | -1.31% | 68.58% | | EBITDA (ttm): | -11.56M | 7.74B | N/A | -16.09M | -6.21M | | Oper Margins (ttm): | -72.90% | 30.97% | N/A | -19.54% | 2.25% | | Net Income (ttm): | -29.82M | -216.00M | N/A | -11.27M | N/A | | EPS (ttm): | -0.358 | -0.197 | N/A | 1.617 | -0.17 | | P/E (ttm): | N/A | N/A | N/A | 6.92 | 18.31 | | PEG (5 yr expected): | N/A | 4.05 | N/A | 0.25 | 1.01 | | P/S (ttm): | 9.18 | 2.03 | N/A | 9.21 | 4.36 |
|
| LLY = Eli Lilly & Co. | | GNTA.OB = Genta Inc. | | ISIS = Isis Pharmaceuticals, Inc. | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.53 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | LLY | | Sitting Atop An Earnings Powder Keg
Wed 4:10pm -
at Forbes.com | | • | LLY | | A Big Upgrade for Amylin Pharmaceuticals
Wed 3:20pm -
at Motley Fool | | • | LLY | | 7 Dividend Divas
Wed 2:12pm -
at Motley Fool | | • | LLY | | Do Good Without Being a Corporate Hotshot
Wed 9:48am -
at Motley Fool | | • | ISIS | | Genzyme's Renagel / Renvela Franchise: Investors Would Be Wise to Reevaluate
Wed 7:31am -
at Seeking Alpha | | • | LLY | | Forgetful patients lift support consultancies
Tue, Nov 24 -
at FT.com | | • | ISIS | | Isis Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Tue, Nov 24 -
PR Newswire | | • | ISIS | | Genzyme's Very Bad Year
Mon, Nov 23 -
at Seeking Alpha | | • | ISIS | | 5 Superball Stocks
Mon, Nov 23 -
at Motley Fool | | • | ISIS | | Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Mon, Nov 23 -
PR Newswire | | • | ISIS | | Stocks Doing Right By Shareholders
Thu, Nov 19 -
at Motley Fool | | • | ISIS | | Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation
Thu, Nov 19 -
PR Newswire | | • | GNTA.OB | | Genta Announces Closing of $10 Million in Two Offerings of Common Stock and Convertible Notes
Fri, Sep 4 -
Business Wire | | • | GNTA.OB | | Hot Biotech Events for Next Week: BioBuzz
Fri, Sep 4 -
at TheStreet.com | | • | GNTA.OB | | GENTA INC DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
Wed, Jul 8 -
EDGAR Online | | • | GNTA.OB | | GENTA INC DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Tue, Jun 30 -
EDGAR Online | | • | GNTA.OB | | GENTA INC DE/ Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Fri, Jun 5 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
0.01 (0.67%) 
Competitors
